Table 3.
Therapeutic effects of heart rate reduction by ivabradine in heart failure patients with systolic dysfunction and sinus rhythm ≥ 75/min – data from the SHIFT
| In patients with systolic heart failure (sinus rhythm; NYHA II–IV; EF < 35%; f >/= 75/min; follow-up 2.5 years) | |
| Ivabradine treatment achieves | |
| Heart failure hospitalization | ↓ 30% (p < 0.0001) |
| Cardiovascular mortality | ↓ 17% (p = 0.0166) |
| Heart failure mortality | ↓ 39% (p < 0.0006) |
| Best effect | |
| f < 60/min or heart rate reduction > 10/min after 28 days | |
Note: Data from the SHIFT study.27
Abbreviations: EF, ejection fraction; f, heart rate; NYHA, New York Heart Association.